Erick

Membranous nephropathy treatment standard More info: academic.oup.com/ndt/article/39… @NDTsocial, @vinckcaro, @hjanders_hans, @ERAkidney

Effects of Empagliflozin on Urine Biomarkers in EMPA-KIDNEY bit.ly/3WA9uoy #OpenAccess @grecombm @NatalieStaplin @Dilushiwijay @KillianDonovan @doreen_zhu @kayzieb77 @sarahngyoonai @KatherineTuttl8 @MartinLandray @ChristophWanne4 @shlipak_khrc @willkidney @Oxford_NDPH

En hemodiálisis, el ultrasonido pulmonar hecho por enfermería para decidir el ultrafiltrado, comparado a lo habitual: •↑200ml ultrafiltrado •↓2.1 kg peso seco •↓5 líneas B •↓41% riesgo de congestión pulmonar En ensayo clínico Kidney360 2026 doi.org/10.34067/KID.0…

Editors’ Choice 2025: Acute Kidney Injury Associated with Novel Anticancer Therapies: Immunotherapy In this article, authors detail the mechanism of action of novel therapies, along with the diagnosis and management of their kidney adverse effects. Check out the paper here: kidney.pub/KID0749

Comparto nuestro nuevo articulo en @ASNKidney360 Colaboración de @NefroINCMNSZ y @Issemym #ecatepians -134 px en UCI ➡️ AKI 15% -Indice Angina Renal (mRai) + [TIMP2] x [GFBP7] ✅ Predice AKI con AUC 0.82 @erick_yasar @karla_linro @chayilu7 @Noemi_nefro @Yazmin_7Mercado

@JonathanNefro Buen ejemplo de clinical trial emulado (metodología y deficiencias). Hay que ser cautelosos con la interpretación: -El trasplante SI mejora sobrevida frente a diálisis en todos los escenarios. -Las condiciones del receptor son determinantes y deben guiar la asignación del órgano.

Recibir un trasplante renal cadavérico con puntaje KDRI bajo (bajo riesgo de perder el injerto), comparado a mantenerse en lista de espera, se asoció a vivir únicamente 6 meses más. En KDRI alto, no hay beneficio en sobrevida JAMA Intern Med 2025 10.1001/jamainternmed.2025.5624

@JonathanNefro Limitantes importantes: -El riesgo inmunológico no fue considerado en el modelo. Aun así, incluso los pacientes añosos muestran beneficio con ofertas de órganos marginales.

Effects of SGLT2 inhibitors in lupus nephritis CKD. In this before-and-after study we explored the changes in proteinuria, eGFR, hemoglobin, and other parameters in the 12 months before and after SGLT2 initiation. shorturl.at/1gDGT @RheumJnl @NefroINCMNSZ

Predicting Chronic Kidney Disease After Cisplatin Treatment Using Population-Level Data | Oncology | JAMA Oncology | JAMA Network jamanetwork.com/journals/jamao…

🔍Refractory GN? Think cancer!🦀 🫘MN, MCD, IgAN, MGRS — when & who to screen? 👇Must-see visual guide 🧵A brilliant #CKJReview by Murt et al 📖doi.org/10.1093/ckj/sf… 🆕 #MedEd #Nephrology #GlomerularDisease #OncoNephrology

Ten Tips for an Onco-Nephrology Clinic doi.org/10.1093/ckj/sf…

Ten tips for an OncoNephrology clinic! A must read! Another strong work Dr @delphile ! @MayoClinicNeph @onconephsociety @CKJsocial #onconephrology

@Omar_Fueyo @goKDIGO Jajajajajaa al fin

@goKDIGO Tanto la pediste @erick_yasar

We are pleased to announce the publication of the KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Read the news release: kdigo.co/2025-ADPKD-Gui… This first-ever KDIGO guideline focused on a rare kidney disease provides practical tools for healthcare providers and patients to improve diagnosis, care, and treatment, addressing challenges in managing this inherited condition. "This comprehensive guideline reflects the significant progress in ADPKD research over the last decade, from genetic insights to advanced therapies," said Guideline Co-Chair Vicente E. Torres, MD. "By addressing the complexities of diagnosis, treatment, and management, we hope this guideline will standardize care, enhance clinical practices, and help reduce the global burden of ADPKD. Our goal is that this resource will not only empower clinical decision-making but also inspire hope for patients and their families, demonstrating that meaningful progress is achievable for this challenging disease." "The publication of this guideline represents a pivotal step forward in the care of ADPKD and people with rare genetic disorders worldwide," said Guideline Co-Chair Olivier Devuyst, MD. "It is the result of an extraordinary global collaboration among experts, researchers, and patient advocates, bringing together the best available evidence to guide care across diverse settings. This guideline is not just important for individuals with ADPKD. It also serves as a crucial template for the development of guidance for other rare genetic conditions. By providing a roadmap for consistent, evidence-based care, it addresses critical knowledge and practice gaps worldwide, offering a model for improving the lives of those with rare diseases globally." Download the KDIGO ADPKD Guideline, Executive Summary, and Data Supplement on the guideline website: kdigo.co/ADPKD Read the guideline in @Kidney_Int: kdigo.co/ADPKD-Guidelin… #ADPKD

Just published 🆕 @goKDIGO Clinical Practice Guideline for the Evaluation, Management, and Treatment of ADPKD ca. 2025 #Nephpearls 👉 kdigo.org/guidelines/aut…

Changing treatment paradigms for membranous nephropathies 🆓doi.org/10.1093/ndt/gf…

Acute Kidney Disease in Oncology: A New Concept to Enhance the Understanding of the Impact of Kidney Injury in Patients with Cancer | Kidney and Blood Pressure Research | Karger Publishers karger.com/kbr/article/49…

🫘💯Approach to Autosomal dominant tubulointerstitial kidney disease academic.oup.com/ndt/article/38… @NDTsocial @hjanders_hans

📢#PKDPearls Diagnostic algorithm for adults with kidney cysts and: ✅Family history of ADPKD ❎Incidental findings #nephtwitter #nephrogenetics

Concomitant Sparsentan (SPAR) and SGLT2 Inhibitors (SGLT2i) in Adults with 🔬 IgA Nephropathy (IgAN) in the Ongoing Phase 2 SPARTACUS Trial #Nephpearls #KidneyWk